Shopping Cart
Remove All
Your shopping cart is currently empty
Actoxumab is a humanized monoclonal antibody targeting Clostridium difficile toxin A (TcdA), preventing the binding of TcdA to target cells and neutralizing toxin activity by inhibiting the first step of TcdA.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $332 | In Stock | In Stock | |
| 5 mg | $996 | In Stock | In Stock | |
| 10 mg | $1,577 | - | In Stock | |
| 25 mg | $2,680 | - | In Stock |
| Description | Actoxumab is a humanized monoclonal antibody targeting Clostridium difficile toxin A (TcdA), preventing the binding of TcdA to target cells and neutralizing toxin activity by inhibiting the first step of TcdA. |
| In vitro | Actoxumab (10 mg/kg) significantly inhibited cell rounding activity in Vero cells when treated with 2 ng/mL TcdA. [1] |
| In vivo | Actoxumab-bezlotoxumab (0.1, 1 or 10 mg/kg) significantly protected mice in a dose-dependent manner from Clostridium difficile toxin attack models. In acute and severe CDI models, Actoxumab-bezlotoxumab prevents inflammation and damage associated with TcdA and TcdB. [1] |
| Synonyms | Anti-C. difficile Toxin A Recombinant Antibody |
| Cas No. | 1245634-25-6 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.